SIAS
LXRX icon

Shine Investment Advisory Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Shine Investment Advisory Services’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$0 Hold
10
– – ﹤0.01% 747
2020
Q2 		$0 Hold
10
– – ﹤0.01% 752
2020
Q1 		$0 Hold
10
– – ﹤0.01% 748
2019
Q4 		$0 Buy
+10
New +$38 ﹤0.01% 756

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Shine Investment Advisory Services's LXRX Position: Q3 2020 in Review

Shine Investment Advisory Services held its Lexicon Pharmaceuticals (LXRX) position steady in Q3 2020 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Shine Investment Advisory Services first reported a position in LXRX in Q4 2019 and has held it in 4 quarters since. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • Shine Investment Advisory Services held 10 shares of Lexicon Pharmaceuticals worth $0 as of Q3 2020.
  • Shine Investment Advisory Services left its Lexicon Pharmaceuticals share count unchanged in Q3 2020.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Shine Investment Advisory Services's portfolio in Q3 2020, its #747 holding.
  • Shine Investment Advisory Services first reported a position in Lexicon Pharmaceuticals in Q4 2019 and has held it in 4 quarters since.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Shine Investment Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.